title: The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
authors.affiliation: Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: W A
authors.initials: WA
authors.lastname: Gattis
authors.forename: T J
authors.initials: TJ
authors.lastname: Ryan
mesh_terms: D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data*; D006801:Humans; D015203:Reproducibility of Results; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents